5、消化系统肿瘤消化系统肿瘤 (26).pdf

《5、消化系统肿瘤消化系统肿瘤 (26).pdf》由会员分享，可在线阅读，更多相关《5、消化系统肿瘤消化系统肿瘤 (26).pdf（5页珍藏版）》请在得力文库 - 分享文档赚钱的网站上搜索。

1、 Journal of Clinical Oncology List of Issues Volume 39,Issue 15_suppl Meeting Abstract|2021 ASCO Annual Meeting IGASTROINTESTINAL CANCERGASTROESOPHAGEAL,PANCREATIC,ANDHEPATOBILIARYLenvatinib plus toripalimab as first-linetreatment for advanced intrahepaticRights&PermissionsOPTIONS&TOOLSExport Citati

2、onTrack CitationAdd To FavoritesADVERTISEMENTADADVERTISEMENTLog InSubmitE-AlertsCartOpenAthens/Shibboleth MENU Article Toolscholangiocarcinoma:A single-arm,phase 2trial.Zhou Jian,Jia Fan,Guo-Ming Shi,Xiao-Yong Huang,Dong Wu,Fei Liang,.Show MoreAbstract Disclosures4099Background:Lenvatinib monotherap

3、y andlenvatinib plus PD-1 antibody have shown someclinical benefit for advanced intrahepaticcholangiocarcinoma(ICC)in the second-linesetting.Our study assesses the role of lenvatinibplus toripalimab(PD-1 antibody)for advanced ICCpatients as the first line therapy.Methods:Patients(pts)with locally ad

4、vanced or metastaticICC received 12 mg/day(Body Weight 60 kg)or 8mg/day(Body Weight 60 kg)oral lenvatinib dailyplus 240 mg intravenous toripalimab every 3COMPANION ARTICLESNo companion articlesARTICLE CITATIONDOI:10.1200/JCO.2021.39.15_suppl.4099Journal of Clinical Oncology 39,no.15_suppl(May 20,202

5、1)4099-4099.Published online May 28,2021.WE RECOMMENDADVERTISEMENTEmployer:Merritt HawkinsApply for this job Employer:Potomac Oncology&HematologyApply for this job Hematology-Oncology OpportunityJust Outside of ChicagoRockford,Illinois N/AA reputable integrated health system seekinga board-certified

6、 or board-eligiblehematologist-oncologist to join its team.Oncology&Hematology AssociatePositionRockville,Maryland Competitive SalaryThis position offers a competitive base salary,a comprehensive benefits package,exceptional productivity incentives,and apartnership track.Hematology/Oncology-at the B

7、each inLow Tax Delaware!Delaware(US);Family-oriented resort area inbeautiful south coastal DelawareAbstractData from ESMO,GU CancersSymposium Highlight Progress inKidney Cancer TreatmentTeresa Alonso Gordoa et al.,ASCODaily News,2021Phase Ib Study of Lenvatinib PlusPembrolizumab in Patients WithUnre

8、sectable HepatocellularCarcinomaRichard S.Finn et al.,J Clin Oncol,2020ESMO 2019:Ivosidenib in IDH1-Mutated AdvancedCholangiocarcinomaBy The ASCO Post Staff,The ASCOPost,2019weeks.The primary endpoint was objectiveresponse rate(ORR)and evaluated according toResponse Evaluation Criteria In Solid Tumo

9、rsversion 1.1(RECIST v1.1).Secondary endpointsincluded safety,progression-free survival(PFS)and overall survival(OS).Treatment continueduntil confirmed disease progression,unacceptabletoxicity,or voluntary withdrawal.This trial isregistered with ClinicalTrials.gov(NCT04361331).Results:From March 202

10、0 to Sep.2020,31pathologically confirmed advanced ICC pts with amean age of 58.4(range,25-73)years,including18 women(58.0%),were enrolled at ZhongshanHospital,Fudan University.At the end of lastfollow-up(February 10,2021),the ORR was 32.3%(10/31;95%CI:16.7%-51.4%)and the diseasecontrol rate(DCR)was

11、74.2%(23/31;95%CI:55.4%-88.1%).Median follow-up was 6.9 months.Two pts with locally advanced disease were down-staged and then underwent resection.Theyremained disease-free survival at the end of lastfollow-up.11 pts exerted disease progression and7 pts died.The median PFS and OS have not beenADVERT

12、ISEMENTA multicenter phase II study ofcapecitabine plus oxaliplatin(CapOx)in advanced biliary systemadenocarcinomasO.Nehls et al.,J Clin Oncol,20042018 ASCO:KEYNOTE-427 TrialEvaluates Pembrolizumab inAdvanced Clear Cell Renal CellCarcinomaBy The ASCO Post,The ASCO Post,2018Limited Benefit of Pembrol

13、izumabMonotherapy in Metastatic TNBCBy staff,US Pharmacist,2021Comparison and analysis of theefficacy of drug therapy for livercancerPhilippe Merle et al.,HepatomaResearch-OAE Publishing,2020STRATUS MM-010 Trial:Pomalidomide Plus Low-DoseDexamethasone inRelapsed/Refractory MultipleMyelomaASH Clinica

14、l NewsCurrent and future drugcombination strategies based onprogrammed death-1/programmeddeath-ligand 1 inhibitors in non-small cell lung cancerYing Li Cheng et al.,Chinese MedicalJournal,2021Systemic therapy for advancedcholangiocarcinoma:new options onthe horizonreached.Median duration of response

15、(DOR)hasnot been reached and responses were ongoing in9/10(90.0%)pts at data cutoff.6-months OS ratewas 87.1%.No grade 5 adverse event(AE)wasobserved in present study.32.3%(10/31)of ptsexperienced Grade 3 or higher AEs and 1 ptsdiscontinued the treatment owing to severefatigue.Conclusions:As the fir

16、st-line therapy,lenvatinib plus toripalimab provided promisingefficacy with reasonable safety profile in advancedICC patients.It offered an alternative treatmentfor advanced ICC who cannot tolerategemcitabine-based chemotherapy.Clinical trialinformation:NCT04361331.2021 by American Society of Clinic

17、al OncologyResearch Sponsor:NoneSaleh A.Alqahtani et al.,HepatomaResearch-OAE Publishing,2020Powered byQUICK LINKSContentResourcesASCO FAMILY OF SITESJournalsEducationNewest Articles Archive Meeting AbstractsJournal InformationAbout Editorial Roster Contact Us PermissionsAuthors Reviewers Subscriber

18、s Institutions AdvertisersSubmit Your ManuscriptSubscribe to this JournalJournal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision OncologyPublicationsASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post ASCO eLearning ASCO Meetings Cancer.NetOther SitesASCO.org ASCO Author Services ASCO Career Center CancerLinQ Conquer Cancer Foundation TAPUR Study American Society of Clinical Oncology2318 Mill Road,Suite 800,Alexandria,VA 22314 2021 American Society of Clinical Oncology Terms of Use|Privacy Policy|Cookies